Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000; 88 :770–776. doi: 10.1002/(SICI)1097-0142(20000215)88:43.0.CO;2-0. [ Cross Ref ]...
Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This ...
Treatment of the carcinoid syndrome with SMS 201-995;a somatostatin analogue. Scand J Gastroenterol 1986;119:191-2.Öberg, K., Norheim, I., Lundqvist, G., and Wide, L. (1986). Treatment of the carcinoid syndrome with SMS 201-995, a somatostatin analouge. Scand J Gastroenterol 119 , ...
Read about carcinoid tumor treatment, symptoms, and meaning. Carcinoid tumors in the lungs or gut often have no symptoms, however, they may cause carcinoid syndrome. Learn the symptoms, treatment, and prognosis of carcinoid tumors.
of somatostatin or a synthetic derivative thereof, interferon, 5-fluorouracil, doxorubicin, cyclophosphamide, streptozotocin and a standard anti-diarrheal, for the preparation of a medicament for the treatment of carcinoid syndrome or at least one neuroendocrine tumor; a method of treating a warm-...
The use of recombinant IFN-alpha-2a at these doses is well-tolerated and effective in controlling carcinoid syndrome (complete remission plus partial remission, 64%), although it has limited activity on tumor growth inhibition. No definitive data can be given for the other protocol treatments....
Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Prolonged release Lanreotide provides good symptomatic control of diarrhoea and flushing as well as tumour stability in patients with malignant carcinoid syndrome... MS Khan,F El-Khouly,...
Recent findings: Over the last few years there have been a number of advances in all aspects of carcinoid syndrome as well as new therapies. These include new studies on its epidemiology which demonstrate it is increasing in frequency; increasing insights into the pathogenesis of its various......
Medical therapy for carcinoid heart disease includes digitalis and diuretics for congestive heart failure symptoms; the effects of carcinoid syndrome can be treated with the use of somatostatin analogues. Conventional chemotherapy has been of little beneficial value, with response rates of only 10% to ...
The incidence of functioning NETs ranges from 0.01–8.4 cases per 100,000 per year, depending on the secreted hormone. Carcinoid syndrome is the most frequent hormone-related syndrome within NETs (2–8.4 new cases/100,000/year) and is predominantly encountered in patients with metastasized midgut...